Aclarion, Inc. (ACONW) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Aclarion, Inc. (ACONW) Healthcare & Pipeline Overview

Aclarion, Inc. is a healthcare technology company specializing in software applications for magnetic resonance spectroscopy (MRS), primarily focused on calculating degenerative pain biomarkers for lower back pain. Its NOCISCAN-LS Post-Processor suite provides objective diagnostic support, addressing an unmet need in spinal pain assessment within the US healthcare market.

What Is the Investment Thesis for ACONW?

Aclarion, Inc. operates in the specialized healthcare technology sector, focusing on objective diagnostics for lower back pain through its magnetic resonance spectroscopy (MRS) software. The core investment thesis centers on the significant unmet need for precise, objective diagnostic tools in the vast lower back pain market, which currently relies heavily on subjective assessments. Aclarion's NOCISCAN-LS Post-Processor suite, including NOCICALC-LS and NOCIGRAM-LS, offers a potential solution by quantifying degenerative pain biomarkers. The company's beta of 1.44 suggests higher volatility relative to the market. However, Aclarion faces substantial financial challenges, evidenced by a very small market capitalization of $0.00B and a deeply negative profit margin of -10336.1% and gross margin of -58.9%. These metrics indicate significant financial risk and potential delisting concerns. Future value drivers would include successful market adoption of its diagnostic software, securing additional funding to extend its cash runway, and achieving profitability through increased sales and operational efficiency. Investors would need to monitor the company's ability to overcome its current financial distress and capitalize on the market demand for objective pain diagnostics.

Based on FMP financials and quantitative analysis

ACONW Key Highlights

• Market Capitalization: $0.00B, indicating a micro-cap status and significant financial scale challenges.
• Profit Margin: -10336.1%, reflecting substantial operating losses relative to revenue.
• Gross Margin: -58.9%, suggesting that the cost of goods sold significantly exceeds revenue.
• Beta: 1.44, indicating the stock's price is more volatile than the overall market.
• Employee Count: 5 employees, highlighting a lean operational structure for a healthcare technology company.

Who Are ACONW's Competitors?

ACONW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ACONW's Key Strengths?

• Addresses a significant unmet need for objective diagnostics in the large lower back pain market.
• Proprietary software suite (NOCISCAN-LS) leveraging magnetic resonance spectroscopy (MRS) for biomarker quantification.
• Offers a differentiated approach to spinal pain detection compared to subjective methods.

What Are ACONW's Weaknesses?

• Very small market capitalization ($0.00B) and low share price.
• Significant financial challenges, including deeply negative profit (-10336.1%) and gross (-58.9%) margins.
• Potential for delisting concerns due to financial distress and limited cash runway.
• Small operational team of 5 employees, potentially limiting scalability and development speed.

What Could Drive ACONW Stock Higher?

• Successful securing of additional funding rounds to extend operational runway and support product commercialization efforts.
• Achievement of significant regulatory milestones or expanded clearances for the NOCISCAN-LS Post-Processor suite, potentially broadening its clinical indications or market access.
• Formation of strategic partnerships or distribution agreements with major medical imaging companies or large hospital networks, accelerating market adoption.
• Increasing adoption rates and positive clinical outcomes demonstrating the efficacy and utility of NOCISCAN-LS in objective lower back pain diagnosis.
• Introduction of enhanced software features or new applications for MRS technology beyond current lower back pain diagnostics.

What Are the Key Risks for ACONW?

• Financial-distress signal — its Altman Z-Score of -4.40 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-54.4%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Significant financial instability, characterized by a $0.00B market capitalization, deeply negative profit margin of -10336.1%, and gross margin of -58.9%, posing substantial going concern risks.
• Potential for delisting from public exchanges due to its very small market capitalization and low share price, which could further limit access to capital and investor interest.
• Limited cash runway and the inability to secure additional funding, which could impede ongoing research, development, and commercialization efforts.
• Intense competition from larger, more established medical device and diagnostic companies with greater financial resources and market presence.
• Slow or limited market adoption of its specialized MRS software by healthcare providers, potentially due to unfamiliarity with the technology or integration challenges.

What Are the Growth Opportunities for ACONW?

• Expansion of NOCISCAN-LS Adoption in Diagnostic Centers: A significant growth opportunity lies in increasing the penetration and utilization of the NOCISCAN-LS Post-Processor suite within existing and new diagnostic imaging centers across the United States. The market for advanced diagnostic tools in spinal care is substantial, driven by the prevalence of lower back pain. By demonstrating clear clinical utility and cost-effectiveness, Aclarion can drive adoption among radiologists and pain specialists. Focused marketing and sales efforts, potentially through partnerships with imaging equipment manufacturers or large hospital networks, could accelerate market share gains over the next 3-5 years, tapping into the multi-billion dollar medical imaging software market.
• Development of New Applications for MRS Technology: While currently focused on lower back pain, the underlying magnetic resonance spectroscopy (MRS) technology has potential applications in diagnosing other conditions where biomarker quantification is crucial, such as neurological disorders, oncology, or musculoskeletal issues beyond the spine. Expanding the NOCISCAN-LS suite to address these broader diagnostic needs could unlock new, larger market segments. This diversification would require further research and development, clinical trials, and regulatory approvals, representing a medium to long-term growth driver (5-10 years) with the potential to access multi-billion dollar diagnostic markets.
• Geographic Expansion Beyond the US Market: Aclarion currently operates primarily in the United States. Expanding its market reach into international territories, particularly in regions with high healthcare expenditure and a significant prevalence of lower back pain, such as Europe or parts of Asia, presents a substantial growth opportunity. This would involve navigating diverse regulatory environments, establishing international distribution channels, and adapting the software for local healthcare practices. Such expansion could significantly broaden the company's addressable market, potentially doubling or tripling its revenue potential over a 5-7 year horizon, contingent on successful market entry strategies.
• Strategic Partnerships with Medical Device Manufacturers: Collaborating with established medical device companies that produce MRI scanners or other diagnostic equipment could provide Aclarion with integrated market access and validation. Integrating NOCISCAN-LS directly into existing MRI workflows or offering it as a bundled solution could accelerate adoption rates and reduce sales cycle times. These partnerships could range from co-marketing agreements to licensing deals, offering a capital-efficient way to scale. Such alliances could provide significant leverage within 2-4 years, tapping into the global medical imaging market, valued at hundreds of billions of dollars.
• Enhancement of Software Capabilities with AI/ML: Integrating artificial intelligence and machine learning algorithms into the NOCISCAN-LS suite could significantly enhance its diagnostic accuracy, efficiency, and predictive capabilities. AI could automate data processing, identify subtle patterns in MRS data that human eyes might miss, and even predict treatment responses based on biomarker profiles. This technological advancement would strengthen Aclarion's competitive moat, improve clinical outcomes, and potentially lead to new revenue streams through advanced analytics services. This innovation pathway represents a continuous growth opportunity over the next 2-5 years, positioning Aclarion at the forefront of AI-driven medical diagnostics.

What Opportunities Does ACONW Have?

• Expand market adoption of NOCISCAN-LS within diagnostic centers and hospitals.
• Develop new applications for MRS technology beyond lower back pain diagnostics.
• Form strategic partnerships with larger medical device or imaging companies for wider market access.
• Geographic expansion into international markets with high demand for advanced diagnostics.

What Threats Does ACONW Face?

• Intense competition from larger, more established medical device and diagnostic companies with greater financial resources and market presence.
• Challenges in securing additional funding to sustain operations and fuel growth.
• Regulatory hurdles and lengthy approval processes for medical diagnostic software.
• Potential for limited market acceptance or slow adoption by healthcare providers.
• Risk of technological obsolescence or emergence of superior diagnostic methods.

What Are ACONW's Competitive Advantages?

• Specialized MRS Software: Focus on magnetic resonance spectroscopy for biomarker quantification provides a niche expertise not widely available from general imaging software providers.
• Proprietary Algorithms: Development of unique algorithms within NOCICALC-LS for calculating degenerative pain biomarkers offers a distinct technological advantage.
• Clinical Decision Support Integration: NOCIGRAM-LS provides integrated clinical decision support, enhancing the utility and interpretability of complex MRS data for clinicians.
• Addressing Unmet Need: Directly targets the significant market gap for objective diagnostics in lower back pain, potentially establishing an early mover advantage in this specific application.

What Does ACONW Do?

Aclarion, Inc., founded in 2008 and originally known as Nocimed, Inc. before its rebranding in December 2021, is a healthcare technology company headquartered in San Mateo, California, with operations based in Broomfield, US. The company is dedicated to developing advanced software applications that leverage magnetic resonance spectroscopy (MRS) for diagnostic purposes within the United States. Aclarion's core product offering is the NOCISCAN-LS Post-Processor suite, a sophisticated system designed to enhance the diagnostic capabilities for lower back pain. This suite comprises two primary components: NOCICALC-LS and NOCIGRAM-LS. NOCICALC-LS is engineered to receive and meticulously process acquired disc MRS data, enabling the precise calculation of levels of degenerative pain biomarkers. This functionality provides objective, quantitative data crucial for understanding the underlying causes of spinal pain, moving beyond subjective patient reporting or less specific imaging. Complementing NOCICALC-LS, NOCIGRAM-LS serves as a clinical decision support software. It assists healthcare professionals in interpreting the complex MRS data and biomarker calculations, thereby facilitating more informed and accurate diagnostic decisions regarding lower back pain. Aclarion's strategic focus lies in addressing the significant unmet need for objective diagnostics in the lower back pain market, a condition affecting millions globally and often challenging to diagnose precisely. By providing tools that can improve patient outcomes and streamline treatment pathways, the company aims to reduce healthcare costs associated with misdiagnosis and ineffective treatments. Despite its small team of 5 employees, the company positions itself as an innovator in medical diagnostics, striving to commercialize products that offer a more precise approach to detecting spinal pain compared to traditional subjective methods, thereby establishing a unique niche in the medical imaging software sector.

What Products and Services Does ACONW Offer?

• Develops software applications for magnetic resonance spectroscopy (MRS) in the United States.
• Offers the NOCISCAN-LS Post-Processor suite, specifically for lower back pain diagnostics.
• Provides NOCICALC-LS, a component that processes MRS data to calculate degenerative pain biomarkers.
• Includes NOCIGRAM-LS, a clinical decision support software that aids in interpreting MRS data.
• Aims to provide objective diagnostic tools for lower back pain, addressing an unmet market need.
• Focuses on quantifying biomarkers to improve the precision of spinal pain detection.
• Contributes to more informed clinical decisions for patients suffering from lower back pain.

How Does ACONW Make Money?

• Software Licensing/Sales: Generates revenue through the direct sale or licensing of its NOCISCAN-LS Post-Processor suite to healthcare providers, diagnostic centers, and hospitals.
• Service Fees: Potentially earns revenue from ongoing maintenance, support, and updates for its specialized diagnostic software.
• Data Processing Fees: May charge per-scan or subscription fees for the processing and analysis of MRS data through its NOCICALC-LS component.
• Clinical Decision Support: Provides value through its NOCIGRAM-LS software, which enhances diagnostic accuracy and efficiency for clinicians.

What Industry Does ACONW Operate In?

Aclarion, Inc. operates within the Medical - Healthcare Information Services industry, specifically targeting the diagnostic segment for lower back pain. This sector is characterized by a growing demand for objective, data-driven solutions to improve patient care and reduce healthcare costs. The broader market for spinal diagnostics and pain management is substantial, driven by an an aging population and increasing prevalence of chronic back conditions. Currently, lower back pain diagnosis often relies on subjective patient reporting and general imaging, leading to variability in treatment outcomes. Aclarion positions itself by addressing this critical unmet need with its magnetic resonance spectroscopy (MRS) software, NOCISCAN-LS. The competitive landscape includes established medical imaging companies and emerging diagnostic technology firms. Aclarion's niche is its focus on biomarker quantification via MRS, offering a differentiated approach compared to traditional imaging or purely symptomatic assessments. Success in this market hinges on clinical validation, regulatory approvals, and widespread adoption by healthcare providers who seek more precise diagnostic tools.

Who Are ACONW's Key Customers?

• Diagnostic Imaging Centers: Facilities that perform MRI scans and require advanced software for interpreting specialized MRS data.
• Hospitals and Healthcare Systems: Large medical institutions seeking to improve diagnostic accuracy and patient outcomes for lower back pain.
• Pain Management Clinics: Specialized clinics focused on diagnosing and treating chronic pain conditions, particularly spinal pain.
• Radiologists and Neurologists: Medical professionals who utilize imaging and spectroscopy data for patient diagnosis and treatment planning.

FY2026 estForward Outlook

Wall Street analysts project Aclarion, Inc. revenue of about $140K for fiscal 2026, with EPS near $-4.51.

F-Score 1/9Financial Health

Aclarion, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.40 places it in the distress zone, a signal of elevated financial risk.

ROE -54%Key Financial Metrics

Return on equity for Aclarion, Inc. stands at -54.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -39.0%, showing how much profit it generates from its asset base. A current ratio of 19.65 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -146.5%, the inverse of the P/E and a quick read on earnings relative to price.

Aclarion, Inc. (ACONW) Valuation Context

Relative to its peer group, ACONW's quantitative score of 55/100 is roughly in line with the peer average of 58/100.

ACONW Revenue & Earnings Trend

In Q1 2026, ACONW generated $21K in top-line revenue, marking a sequential increase of 14.4%. The company recorded a net loss of $2.9M, with diluted EPS of $-1.34. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, ACONW averaged $-2.31 in diluted EPS.

Company Profile

Aclarion, Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Broomfield, US. The company is led by CEO Brent Ness.

ACONW Financials

ACONW Latest News

ACONW Analyst Consensus

ACONW MoonshotScore

Common Questions About ACONW (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources